#cardiomastodon EPA-based therapeutics appear to offer a major advance in #CVD risk reduction that adds to the protection afforded by #statins. REDUCE-IT demonstrated that high doses of a highly purified ethyl ester of EPA, icosapent ethyl, provided large relative and absolute risk reductions in #CVD mortality , #myocardialinfarction, #stroke, hospitalization for #unstableangina, and coronary revascularization in at-risk patients with triglycerides above ≈100 mg/dL despite therapy with statins…